Cargando…
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
BACKGROUND: Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-GBM-1 administration, and (3) survival. METHODS: F...
Autores principales: | Bota, Daniela A., Taylor, Thomas H., Piccioni, David E., Duma, Christopher M., LaRocca, Renato V., Kesari, Santosh, Carrillo, Jose A., Abedi, Mehrdad, Aiken, Robert D., Hsu, Frank P. K., Kong, Xiao-Tang, Hsieh, Candace, Bota, Peter G., Nistor, Gabriel I., Keirstead, Hans S., Dillman, Robert O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749349/ https://www.ncbi.nlm.nih.gov/pubmed/36517865 http://dx.doi.org/10.1186/s13046-022-02552-6 |
Ejemplares similares
-
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023) -
Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines
por: Dillman, Robert O., et al.
Publicado: (2019) -
Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
por: Dillman, Robert Owen, et al.
Publicado: (2019) -
Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
por: Nistor, Gabriel I., et al.
Publicado: (2020) -
Multistep reconstruction of a post-traumatic defect in the lower limb with AV loop and free myocutaneous latissimus dorsi flap combined with a perforator monitor skin island after loss of ALT flap
por: Summer, Tobias, et al.
Publicado: (2021)